Holdings

Palo Alto Investors LP

As of Sep 30, 2026, Palo Alto Investors LP reported 49 positions worth US$628M. Largest: PTC Therapeutics, Inc., Iovance Biotherapeutics, Inc. and Insmed Incorporated. What it bought and sold, with each filing.

Holdings

Positions
49
Value as reported
US$628M
Holdings as of
Sep 30, 2026
Last filed
Nov 16, 2026
CompanySharesValue as reported% of company% of portfolioChangeAs of
PTC Therapeutics, Inc.
NASDAQ:PTCT
875KUS$56.7M8.4%−43,497Sep 30, 2026
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
3.47MUS$51.4M0.75%7.7%−1.82MSep 30, 2026
Insmed Incorporated
NASDAQ:INSM
444KUS$50.6M0.20%7.5%+29,665Sep 30, 2026
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
2.49MUS$50.1M1.4%7.5%−378KSep 30, 2026
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
642KUS$38.5M0.33%5.7%−40,322Sep 30, 2026
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
387KUS$33.1M4.9%+38,506Sep 30, 2026
United Therapeutics Corporation
NASDAQ:UTHR
58,875US$31.9M4.7%−3,712Sep 30, 2026
Dyne Therapeutics, Inc.
NASDAQ:DYN
1.88MUS$30.3M4.5%+234KSep 30, 2026
Biogen Inc.
NASDAQ:BIIB
133KUS$30M0.09%4.5%−7,361Sep 30, 2026
AnaptysBio, Inc.
NASDAQ:ANAB
595KUS$29.9M4.5%−8,225Sep 30, 2026
CareDx, Inc.
NASDAQ:CDNA
425KUS$27.6M0.81%4.1%−107KSep 30, 2026
First Tracks Biotherapeutics, Inc.
NASDAQ:TRAX
741KUS$26.3M1.8%3.9%+138KSep 30, 2026
Disc Medicine, Inc.
NASDAQ:IRON
397KUS$26M0.87%3.9%−20,117Sep 30, 2026
Bicara Therapeutics Inc.
NASDAQ:BCAX
689KUS$12.8M1.9%+139KSep 30, 2026
Annexon, Inc.
NASDAQ:ANNX
2.81MUS$11.9M1.8%−137KSep 30, 2026
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
596KUS$11.2M1.7%−269KSep 30, 2026
Celldex Therapeutics, Inc.
NASDAQ:CLDX
343KUS$11.1M1.7%−56,755Sep 30, 2026
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
710KUS$10.7M1.6%+114KSep 30, 2026
Travere Therapeutics, Inc.
NASDAQ:TVTX
159KUS$9.36M1.4%−8,579Sep 30, 2026
Compass Therapeutics, Inc.
NASDAQ:CMPX
7.15MUS$7.43M4.0%1.1%+1.32MSep 30, 2026
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
201KUS$6.68M0.99%−12,617Sep 30, 2026
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
1.34MUS$6.51M0.41%0.97%−54,165Sep 30, 2026
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
1.16MUS$6.08M0.73%0.90%−457KSep 30, 2026
Capricor Therapeutics, Inc.
NASDAQ:CAPR
548KUS$5.19M0.94%0.77%+318KSep 30, 2026
Align Technology, Inc.
NASDAQ:ALGN
31,389US$4.56M0.68%No changeSep 30, 2026
Protara Therapeutics, Inc.
NASDAQ:TARA
1.04MUS$3.16M1.7%0.47%NewSep 30, 2026
Contineum Therapeutics, Inc.
NASDAQ:CTNM
220KUS$2.96M0.44%NewSep 30, 2026
Edwards Lifesciences Corporation
NYSE:EW
33,640US$2.9M<0.01%0.43%No changeSep 30, 2026
Verastem, Inc.
NASDAQ:VSTM
325KUS$2.62M0.26%0.39%+15,795Sep 30, 2026
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
18,117US$2.57M0.38%No changeSep 30, 2026
Sagimet Biosciences Inc. - Series A
NASDAQ:SGMT
250KUS$2.47M0.36%0.37%No changeSep 30, 2026
Adlai Nortye Group Ltd.
NASDAQ:ANL
149KUS$2.39M0.25%0.36%NewSep 30, 2026
Stoke Therapeutics, Inc.
NASDAQ:STOK
84,631US$2.2M0.33%No changeSep 30, 2026
Oruka Therapeutics, Inc.
NASDAQ:ORKA
25,563US$2.13M0.32%−7,983Sep 30, 2026
Pyxis Oncology, Inc.
NASDAQ:PYXS
864KUS$2.01M0.72%0.30%No changeSep 30, 2026
Cytokinetics, Incorporated
NASDAQ:CYTK
30,036US$1.98M0.29%−2,159Sep 30, 2026
BioNTech SE
NASDAQ:BNTX
19,614US$1.93M<0.01%0.29%NewSep 30, 2026
Nuvation Bio Inc.
NYSE:NUVB
327KUS$1.83M0.09%0.27%No changeSep 30, 2026
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
47,902US$1.78M0.27%−3,443Sep 30, 2026
Humana Inc.
NYSE:HUM
3,985US$1.52M<0.01%0.23%No changeSep 30, 2026
COMPASS Pathways Plc
NASDAQ:CMPS
116KUS$1.44M0.08%0.21%NewSep 30, 2026
eHealth, Inc.
NASDAQ:EHTH
1.43MUS$1.02M4.4%0.15%−51,262Sep 30, 2026
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
104KUS$998K0.06%0.15%No changeSep 30, 2026
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
1,787US$901K<0.01%0.13%No changeSep 30, 2026
Cybin, Inc.
NEO:HELP
72,634US$893K0.10%0.13%NewSep 30, 2026
Bicycle Therapeutics PLC
NASDAQ:BCYC
188KUS$693K0.37%0.10%NewSep 30, 2026
Inspire Medical Systems, Inc.
NYSE:INSP
8,772US$608K0.09%No changeSep 30, 2026
Abeona Therapeutics Inc.
NASDAQ:ABEO
109KUS$572K0.19%0.09%No changeSep 30, 2026
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
156KUS$192K0.26%0.03%No changeSep 30, 2026